Format

Send to

Choose Destination
Int J Cancer. 2015 Nov 15;137(10):2513-9. doi: 10.1002/ijc.29612. Epub 2015 Jun 11.

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.

Author information

1
INSERM U1079, Rouen, France.
2
Department of Gastroenterology, Rouen University Hospital, Rouen, France.
3
Equipe De Recherche En Oncologie (IRON), Rouen University Hospital and Centre Henri Becquerel, Rouen, France.
4
Department of Bio-Pathology, Centre Henri Becquerel, Rouen, France.
5
Department of Pathology, Rouen University Hospital, Rouen, France.
6
Department of Surgery, Clinique Du Cèdre, Bois-Guillaume, France.
7
INSERM U918, Centre Henri Becquerel, Rouen, France.
8
Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.

Abstract

Acquired estrogen receptor gene (ESR1) mutations have been recently reported as a marker of resistance to aromatase inhibitors in hormone receptor positive metastatic breast cancer. We retrospectively considered seven patients treated for metastatic breast cancer with available samples from the primary tumor before any treatment, cryopreserved metastasis removed during progression and concomitant plasmas. All these seven patients were in disease progression after previous exposure to aromatase inhibitors for at least 6 months, and were assessed for ESR1 mutations detection in tumor and circulating DNA. For these patients, Sanger sequencing identified four metastases with clear ESR1 mutation and one possible, whereas digital PCR identified six mutated metastases. Then, under blind conditions and using digital PCR, corresponding circulating ESR1 mutations were successfully detected in four of these six metastatic breast cancer patients. Moreover, in two patients with serial blood samples following treatments exposure, the monitoring of circulating ESR1 mutations clearly predicted disease evolution. In the context of high interest for ESR1 mutations, our results highlight that these acquired recurrent mutations may be tracked in circulating tumor DNA and may be of clinical relevance for metastatic breast cancer patient monitoring.

KEYWORDS:

ESR1 mutations; aromatase inhibitor resistance; circulating tumor DNA; digital PCR; metastatic breast cancer

PMID:
25994408
DOI:
10.1002/ijc.29612
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center